Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paradoxical relationship between acetylator phenotype and amonafide toxicity.

M J Ratain1, R Mick, F Berezin

  • 1Department of Medicine, University of Chicago Pritzker School of Medicine, IL.

Clinical Pharmacology and Therapeutics
|November 1, 1991
PubMed
Summary

Fast acetylators experienced more amonafide toxicity due to increased active metabolite conversion. This suggests personalized dosing strategies for antineoplastic agents based on acetylator phenotype are crucial for patient safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

ESMO open·2025
Same author

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

Nature·2019
Same author

Guideposts on the journey to value.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

Clinical pharmacology and therapeutics·2017
Same author

A research note on the benefit of patient and public involvement in research: The experience of prostate cancer patients regarding information in radiotherapy.

Radiography (London, England : 1995)·2017

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Chemistry

Background:

  • Amonafide is an investigational antineoplastic agent.
  • Individual patient responses to drugs can vary significantly.
  • Acetylator phenotype, determined by drug metabolism, influences drug efficacy and toxicity.

Purpose of the Study:

  • To investigate the relationship between acetylator phenotype and amonafide toxicity.
  • To explore the pharmacokinetic differences in amonafide metabolism based on acetylator status.
  • To identify potential predictors of amonafide-induced toxicity.

Main Methods:

  • Prospective determination of patient acetylator phenotype using caffeine as a test drug.
  • Monitoring for amonafide toxicity, specifically myelosuppression.

Related Experiment Videos

  • Pharmacokinetic analysis, including measurement of the area under the plasma concentration-time curve (AUC) for amonafide.

    • Main Results:

    • Fast acetylators exhibited significantly greater myelosuppression compared to slow acetylators.
    • The AUC of amonafide was significantly higher in fast acetylators, indicating lower total plasma clearance.
    • Pretreatment white blood cell count, patient age, and a higher actual to ideal body weight ratio were independent predictors of leukopenia.

    Conclusions:

    • Acetylator phenotype is a significant factor influencing amonafide toxicity and pharmacokinetics.
    • The observed paradox of lower clearance in fast acetylators may be due to parallel pathway interactions involving the acetylated metabolite.
    • Further studies are needed to establish optimal amonafide dosing for different acetylator subgroups.